| Tocilizumab (Actemra, RoActemra) |
Chugai, Roche |
IL-6R/humanized mAb |
rheumatoid arthritis, systemic juvenile idiopathic arthritis, CD |
approved |
|
|
|
other |
clinical trials |
| REGN-88 (SAR153191) |
Regeneron/Sanofi-Aventis |
IL-6R/human mAb |
rheumatoid arthritis |
clinical trials |
| Siltuximab (CNTO 328) |
Centocor |
IL-6/chimeric mAb |
multiple myeloma, B cell lymphoma, solid tumors |
clinical trials |
| Sirukumab (CNTO 136) |
Centocor |
IL-6/human mAb |
rheumatoid arthritis |
clinical trials |
| B-E8/mAb 1339 |
Diaclone/GlaxoSmithKline |
IL-6/mouse mAb / human mAb |
multiple myeloma/lymphoma |
clinical trials/preclinical |
| FE999301 |
CONARIS/Ferring |
IL-6/sIL-6R complex / soluble gp130-Fc fusion protein |
Crohn's disease |
preclinical |
| Ruxolitinib (Jakafi/Jakavi, INCB018424/INC424) |
Incyte/Novartis |
JAK1/JAK2 |
myelofibrosis; myeloproliferative diseases, leukemia, psoriasis |
approved clinical trials |
